Hualan Biological Engineering (SZSE:002007) ROCE % : 19.71% (As of Sep. 2024)

View and export this data going back to 2004. Start your Free Trial

What is Hualan Biological Engineering ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Hualan Biological Engineering's annualized ROCE % for the quarter that ended in Sep. 2024 was 19.71%.

Hualan Biological Engineering ROCE % Historical Data

The historical data trend for Hualan Biological Engineering's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hualan Biological Engineering ROCE % Chart

Hualan Biological Engineering Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

25.55

28.68

19.60

13.31

16.01

Hualan Biological Engineering Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															26.65	15.83	9.74	6.17	19.71

Hualan Biological Engineering ROCE % Calculation

Hualan Biological Engineering's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	2090.815	/	( ( (14743.379 - 2148.351)	+	(16105.783 - 2581.451) )	/ 2 )
	=	2090.815	/	( (12595.028	+	13524.332)	/ 2 )
	=	2090.815	/	13059.68
	=	16.01 %

Hualan Biological Engineering's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	2672.052	/	( ( (15637.537 - 2334.325)	+	(16101.606 - 2290.64) )	/ 2 )
	=	2672.052	/	( ( 13303.212	+	13810.966 )	/ 2 )
	=	2672.052	/	13557.089
	=	19.71 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

Hualan Biological Engineering (SZSE:002007) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Hualan Biological Engineering ROCE % Related Terms

Thank you for viewing the detailed overview of Hualan Biological Engineering's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hualan Biological Engineering Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hualan Biological Engineering Inc (SZSE:002007) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 1, Hualan Avenue, Henan Province, Xinxiang, CHN, 453003

Website

http://www.hualanbio.com

Hualan Biological Engineering Inc is a China-based biopharmaceutical company. It is engaged in the research, development, production, and commercialization of plasma products, viral vaccines, bacterial vaccines, and recombinant proteins and other biologics. The plasma products offered by the company include Human albumin, Human fibrinogen, Human tetanus immunoglobulin and others. The vaccines products include Recombinant hepatitis B vaccine, Inactivated influenza vaccine and other. It also offers gene products such as Monoclonal Antibody for tumor, autoimmune diseases, infectious diseases, transplant rejection, and Recombinant monoclonal antibodies.

Executives

Chen Zheng Yue	Executives
Fan Bei	Directors, executives
Pan Ruo Wen	Executives
Xie Jun Min	Directors, executives
An Wen Qi	Executives
An Kang	Directors, executives
Ma Xiao Wei	Executives
Zhang Bao Xian	Executives
An Wen Jue	Director
Liu Jun	Executives
Wang Qi Ping	Directors, executives
Lv Cheng Yu	Securities Affairs Representative
Zhang Jin Gang	Independent director
Wang Li Ting	Independent director
Ma Li	Supervisors

Hualan Biological Engineering Headlines

No Headlines